

Financial news for ADHD dated on 2017-11-09: Alcobra Reports Q3 EPS \$(0.09) vs \$(0.38) Est.

Financial news for ADHD dated on 2017-10-20: 38 Biggest Movers From Yesterday

Financial news for ADHD dated on 2017-10-19: Mid-Afternoon Market Update: Crude Oil Down 1.25%; Alcobra Shares Spike Higher

Financial news for ADHD dated on 2017-10-19: 32 Stocks Moving In Thursday's Mid-Day Session

Financial news for ADHD dated on 2017-10-19: Mid-Day Market Update: Heritage-Crystal Clean Drops On Weak Q3 Results; Imprimis Pharmaceuticals Shares Surge

Financial news for ADHD dated on 2017-10-19: Mid-Morning Market Update: Markets Open Lower; Verizon Sales Beat Estimates

Financial news for ADHD dated on 2017-10-19: Arcturus Therapeutics Announces Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines

Financial news for ADHD dated on 2017-10-10: WBB Upgraded Shares Of Alcobra Yesterday Morning From Hold To Speculative Buy, Raised 12-Month Price Target To \$2

Financial news for ADHD dated on 2017-10-09: WBB Securities Raises Alcobra From Hold to Speculative Buy, Sets Price Target At \$2.00

Financial news for ADHD dated on 2017-08-11: Alcobra Reports Q2 EPS \$(0.13) vs \$(0.14) Est.

Financial news for ADHD dated on 2017-06-26: Wall Street's M&A Chatter From June 22-25: Alcobra, Etsy, Sprouts Farmers Market, Whole Foods

Financial news for ADHD dated on 2017-06-23: Alcobra Offers Update On Review Of Strategic Alternatives: Has Engaged Ladenburg Thalmann To Explore, Evaluate Strategic Alternatives

Financial news for ADHD dated on 2017-06-12: Alcobra Reports Cooperation Agreement with Brosh Group and Adds 2 Directors To Board, Will Continue To Review Strategic Alternatives

Financial news for ADHD dated on 2017-06-09: Alcobra Shares Up 21% Premarket; Traders Circulating Article From Calcalist 'Marius Nacht, Yitzhak Petersburg offer to take over Alcobra at a 50% premium on the market price'

Financial news for ADHD dated on 2017-05-30: Alcobra Reports Q1 EPS \$(0.13) vs \$(0.18) Est.

Financial news for ADHD dated on 2017-05-15: Alcobra CEO Dr. Yaron Daniely To Step Down, Names David Baker Interim CEO

Financial news for ADHD dated on 2017-05-05: Alcobra Issues Update on Cancellation of Special Meeting Called by Brosh: Firm Will Withdraw Related Meeting Notice, Proxy Materials, Will Refrain from Initiating Proceedings or Taking Action for Convening Meeting of Holders

Financial news for ADHD dated on 2017-04-24: Alcobra Urges Shareholders to Reject Brosh Group's Efforts to Take Control of Board of Directors -6-K

Financial news for ADHD dated on 2017-04-10: Amended 13D Filing from Exodus Capital on Alcobra Shows Increased Stake to 16.8%

Financial news for ADHD dated on 2017-04-05: Alcobra Says Brosh Capital's Request Does Not Comply With Alcobra's Articles of Association, Addresses Brosh's 'Misinformed Views' In Letter

Financial news for ADHD dated on 2017-03-16: Brosh Capital Expresses Concern with Alcobra's Prolonged Underperformance, Capital Allocation, Board Oversight and Corporate Governance, Nominates 6 Qualified Directors To Replace Board

Financial news for ADHD dated on 2017-02-15: Alcobra Pops to High of \$1.33 on Volume

Financial news for ADHD dated on 2017-02-15: Alcobra Q4 EPS \$(0.22) vs \$(0.27) Est, No Revenue

Financial news for ADHD dated on 2017-02-09: Benzinga's Top Upgrades, Downgrades For February 9, 2017

Financial news for ADHD dated on 2017-02-09: Roth Capital Upgrades Alcobra Ltd. To Buy

Financial news for ADHD dated on 2017-02-06: Alcobra Reports Productive FDA Meeting for New Lead Product Candidate for ADHD

Financial news for ADHD dated on 2017-01-18: Benzinga's Top Upgrades, Downgrades For January 18, 2017

Financial news for ADHD dated on 2017-01-18: Jefferies Downgrades Alcobra Ltd. - Ordinary Shares to Hold, Lowers Target to \$1.25

Financial news for ADHD dated on 2017-01-17: Mid-Afternoon Market Update: Crude Oil Up 1.2%; Progress Software Shares Plunge

Financial news for ADHD dated on 2017-01-17: 12 Biggest Mid-Day Losers For Tuesday

Financial news for ADHD dated on 2017-01-17: Oppenheimer on Alcobra: Highlighting Downside in Stock Tues. (Down ~50%) Puts Market Cap Below Cash Value Near \$50M; Believes Co. Has Potential to Build Upon Current Valuation

Financial news for ADHD dated on 2017-01-17: Mid-Day Market Update: Clayton Williams Energy Surges On Acquisition News; Christopher & Banks Shares Slide

Financial news for ADHD dated on 2017-01-17: Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Tops Q4 Estimates

Financial news for ADHD dated on 2017-01-17: From Conf Call: Alcobra Says Expects to End 2016 With Cash Balance of ~\$50M

Financial news for ADHD dated on 2017-01-17: From Conf Call: Alcobra CEO Says Continuing to Evaluate Promise of MDX in Other Diseases, Including Fragile X Syndrome

Financial news for ADHD dated on 2017-01-17: From Conf Call: Alcobra Says Will Unlikely Continue Development of MDX for ADHD

Financial news for ADHD dated on 2017-01-17: Alcobra Shares Down ~16% Following Halt on Endpoint Miss

Financial news for ADHD dated on 2017-01-17: Alcobra Phase 3 Trial Misses Primary Endpoint

Financial news for ADHD dated on 2017-01-09: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for ADHD dated on 2017-01-05: Option Alert: Alcobra Jan 2.5 Calls: 500 @ ASK \$0.25: 545 traded vs 1091 OI: Earnings 2/16 Before Open (est) \$2.35 Ref

Financial news for ADHD dated on 2016-12-22: Alcobra Spokesperson Tells Benzinga Details Of Update On Recent FDA Meeting On MEASURE Study Clinical Hold Not Likely To Come Until 2017

Financial news for ADHD dated on 2016-12-14: 18 Biggest Mid-Day Losers For Wednesday

Financial news for ADHD dated on 2016-12-14: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ADHD dated on 2016-12-14: Alcobra Says Held Meeting with FDA to Discuss Clinical Hold, Says Expects to Provide More Detail in Coming Weeks

Financial news for ADHD dated on 2016-11-17: Jefferies London Health Care Conference Continues Today

Financial news for ADHD dated on 2016-11-15: Stifel Healthcare Conference Today

Financial news for ADHD dated on 2016-11-15: Alcobra Reports Q3 EPS \$(0.28) vs. Est. \$(0.26)

Financial news for ADHD dated on 2016-11-02: WBB Securities Upgrades Alcobra Ltd. - Ordinary Shares to Hold

Financial news for ADHD dated on 2016-10-28: 7 Biggest Price Target Changes For Friday

Financial news for ADHD dated on 2016-10-28: Barclays Downgrades Alcobra Ltd. - Ordinary Shares to Underweight, Lowers to \$2.00

Financial news for ADHD dated on 2016-09-30: 12 Biggest Mid-Day Losers For Friday

Financial news for ADHD dated on 2016-09-30: Benzinga's Top Downgrades

Financial news for ADHD dated on 2016-09-30: The Market In 5 Minutes: Deutsche Bank Woes Bring Down Indexes

Financial news for ADHD dated on 2016-09-30: PiperJaffray Downgrades Alcobra to Neutral

Financial news for ADHD dated on 2016-09-29: 12 Biggest Mid-Day Losers For Thursday

Financial news for ADHD dated on 2016-09-29: Mid-Day Market Update: Crude Oil Rises Over 2%; Intra-Cellular Therapies Shares Slide

Financial news for ADHD dated on 2016-09-29: Trial Hold And Downgrades Sink Alcobra By 50%

Financial news for ADHD dated on 2016-09-29: Stocks Hitting 52-Week Lows

Financial news for ADHD dated on 2016-09-29: Oppenheimer Downgrades Alcobra to Perform

Financial news for ADHD dated on 2016-09-29: Mid-Morning Market Update: Markets Edge Lower; PepsiCo Beats Q3 Expectations

Financial news for ADHD dated on 2016-09-29: Cantor Fitzgerald Downgrades Alcobra to Hold

Financial news for ADHD dated on 2016-09-29: Alcobra Announces IND Clinical Hold Affecting the MDX Phase III MEASURE Study

Financial news for ADHD dated on 2016-08-30: 10 Biggest Mid-Day Losers For Tuesday

Financial news for ADHD dated on 2016-08-30: Alcobra Q2 EPS (\$0.21) vs (\$0.22) est, No Revenue

Financial news for ADHD dated on 2016-08-30: Earnings Scheduled For August 30, 2016

Financial news for ADHD dated on 2016-08-01: Benzinga's Top Initiations

Financial news for ADHD dated on 2016-08-01: Barclays Initiates Coverage on Alcobra at Equal-weight, Announces \$8.00 PT

Financial news for ADHD dated on 2016-07-19: Alcobra Reports Was Granted EU Orphan Drug Designation for Metadoxine in Fragile X Syndrome

Financial news for ADHD dated on 2016-06-21: Premarket Roth Capital Reinstated Buy on Alcobra

Financial news for ADHD dated on 2016-06-07: Alcobra Shares Initiated At Buy; Cantor Sees 'Greater Opportunity For Success'

Financial news for ADHD dated on 2016-06-07: Cantor Fitzgerald Initiates Coverage on Alcobra at Buy, Announces \$16.00 PT

Financial news for ADHD dated on 2016-05-16: Alcobra Reports Q1 EPS \$(0.18) vs \$(0.22) Est.

Financial news for ADHD dated on 2016-05-16: Earnings Scheduled For May 16, 2016

Financial news for ADHD dated on 2016-02-18: Benzinga's Top Initiations

Financial news for ADHD dated on 2016-02-18: Jefferies Initiates Coverage on Alcobra at Buy

Financial news for ADHD dated on 2016-02-17: Alcobra Reports Q4 EPS \$(0.20) vs \$(0.28) Est.

Financial news for ADHD dated on 2016-02-11: Lockup Expiry For FitBit, Alcobra

Financial news for ADHD dated on 2016-02-04: Earlier Roth Capital Initiated Coverage on Alcobra at Buy

Financial news for ADHD dated on 2016-01-25: Benzinga's Top Initiations

Financial news for ADHD dated on 2016-01-25: Oppenheimer Initiates Coverage on Alcobra at Outperform

Financial news for ADHD dated on 2016-01-08: 13G Filing from Franklin Resources on Alcobra Shows New 10.4% Stake

Financial news for ADHD dated on 2015-11-16: Hayman Capital Adds New Positions

Financial news for ADHD dated on 2015-11-13: 8 Stocks Moving In Friday's After-Hours Session

Financial news for ADHD dated on 2015-11-13: Morning Market Losers

Financial news for ADHD dated on 2015-11-13: Alcobra Prices 6.175M Shares At \$6.50/Share

Financial news for ADHD dated on 2015-11-12: Alcobra Reports Q3 EPS \$(0.20) vs \$(0.31) Est.

Financial news for ADHD dated on 2015-11-12: Alcobra Reports Offering of Ordinary Shares

Financial news for ADHD dated on 2015-09-21: Alcobra Reports FDA Fast Track Designation for MDX for Fragile X Syndrome

Financial news for ADHD dated on 2015-08-13: Roth Captial's Chattopadhyay Reiterates Buy, Raises Target on Alcobra Pharma to \$16, Believes MEASURE Study 'Key Inflection Point'

Financial news for ADHD dated on 2015-06-24: Wednesday's Mid-Day Movers: Fitbit, Transition Therapeutics Losing Big; Celator Pharma, MeetMe Up

Financial news for ADHD dated on 2015-06-24: Morning Market Losers

Financial news for ADHD dated on 2015-06-24: WBB Securities Downgrades Alcobra to Hold

Financial news for ADHD dated on 2015-06-24: Benzinga's Top #PreMarket Losers

Financial news for ADHD dated on 2015-06-24: UPDATE: Alcobra Says Study Did Not Meet Primary Endpoint of Change on ADHD Rs-IV Inattentive Subscale

Financial news for ADHD dated on 2015-06-24: Alcobra Reports Results from Phase 2 Trial of MDX for Fragile X Syndrome

Financial news for ADHD dated on 2015-06-23: Alcobra Ltd. to Highlight Results of Phase II Fragile X Trial in a Conference Call & Webcast Presentation on Wednesday, June 24

Financial news for ADHD dated on 2015-05-06: Alcobra Reports Q1 EPS \$(0.26) vs. Est. (0.29)

Financial news for ADHD dated on 2015-03-10: Morning Market Losers

Financial news for ADHD dated on 2015-03-10: Benzinga's Top #PreMarket Gainers

Financial news for ADHD dated on 2015-03-10: Alcobra's MDX Meets Primary Endpoint in Phase II Safety and Tolerability Clinical Trial In ADHD Children

Financial news for ADHD dated on 2015-02-12: Alcobra Reports Q4 EPS \$-0.50 Vs Est -\$0.60

Financial news for ADHD dated on 2015-01-16: Broadfin Capital Shows 6.8% Passive Stake in Alcobra

Financial news for ADHD dated on 2015-01-16: Deerfield Reports 7% Passive Stake in Alcobra

Financial news for ADHD dated on 2015-01-09: Alcobra Prices 6.5M Shares at \$4/Share

Financial news for ADHD dated on 2015-01-08: Alcobra Commences Public Offering of Ordinary Shares

Financial news for ADHD dated on 2014-11-17: Aegis Capital Downgrades Alcobra Following Q3 Results

Financial news for ADHD dated on 2014-11-17: Aegis Capital Downgrades Alcobra Pharma to Hold

Financial news for ADHD dated on 2014-11-17: Alcobra Pharma Reports Q3 EPS of \$(0.77) vs \$(0.56) Est

Financial news for ADHD dated on 2014-10-23: FBR Capital Downgrades Alcobra Pharma to Market Perform, Lowers PT to \$4.00

Financial news for ADHD dated on 2014-10-23: Midday Losers From October 23: Yelp,

Alcobra, Ultratech

Financial news for ADHD dated on 2014-10-23: Morning Market Losers

Financial news for ADHD dated on 2014-10-23: Alcobra Announces Presentation of New Data From Phase III Adult ADHD Study at AACAP Annual Meeting

Financial news for ADHD dated on 2014-10-07: FBR Capital Downgrades Alcobra Pharma to Hold, Lowers PT to \$9.00

Financial news for ADHD dated on 2014-10-06: Stocks Hitting 52-Week Lows

Financial news for ADHD dated on 2014-10-06: Morning Market Losers

Financial news for ADHD dated on 2014-10-06: Benzinga's Top #PreMarket Losers

Financial news for ADHD dated on 2014-10-06: Alcobra Shares Fall 50% Following Announcement of Topline Results from Phase III Study of MDX in Adult ADHD

Financial news for ADHD dated on 2014-10-06: US Stock Futures Signal Higher Start On Wall Street

Financial news for ADHD dated on 2014-10-06: Alcobra Announces Positive Topline Results from Phase III Study of MDX in Adult ADHD

Financial news for ADHD dated on 2014-09-23: Benzinga's Volume Movers

Financial news for ADHD dated on 2014-09-19: Alcobra Announces Completion Of Phase 3 Trial Of MDX

Financial news for ADHD dated on 2014-09-02: Alcobra Announces Enrollment Of First Patient In Phase IIb Clinical Trial Of MDX In Adolescents With ADHD

Financial news for ADHD dated on 2014-08-27: FBR Capital Initiates Coverage on Alcobra Pharma at Market Perform, Announces \$23.00 PT

Financial news for ADHD dated on 2014-08-19: Alcobra Announces Enrollment of First Patient For Phase IIb Trial of MDX

Financial news for ADHD dated on 2014-08-11: Alcobra Pharma Reports Q2 EPS of \$(0.57); Revenue of \$7.78M

Financial news for ADHD dated on 2014-08-04: Piper Jaffray Initiates Coverage on Alcobra Pharma at Overweight, Announces \$42.00 PT

Financial news for ADHD dated on 2014-08-01: Benzinga's Top Initiations

Financial news for ADHD dated on 2014-08-01: Roth Capital Initiates Alcobra Pharma With Buy

Financial news for ADHD dated on 2014-08-01: Roth Capital Initiates Coverage on Alcobra Pharma at Buy, Announces \$40.00 PT

Financial news for ADHD dated on 2014-07-14: F-3 from Alcobra Shows Registration for \$100M Share Offering

Financial news for ADHD dated on 2014-07-14: Alcobra Announces Completion of Recruitment for Phase III MDX Trial

Financial news for ADHD dated on 2014-06-26: WBB Securities Initiates Coverage on Alcobra Pharma at Hold, Announces \$18.00 PT

Financial news for ADHD dated on 2014-05-15: Alcobra Pharma Reports Q1 EPS of \$(0.57)

Financial news for ADHD dated on 2014-05-08: UPDATE: Alcobra Has Won FDA Clearance for Phase IIB Study of MDX in Fragile X

Financial news for ADHD dated on 2014-05-08: Alcobra Announces FDA Clearance of Protocol for Phase IIb For Metadoxine Extended Release

Financial news for ADHD dated on 2014-04-17: Canaccord Genuity Initiates Coverage on Alcobra Pharma at Buy, Announces \$24.00 PT

Financial news for ADHD dated on 2014-04-10: UPDATE: Alcobra Issues Protocol to FDA for Phase IIb Study of Metadoxine ER for Treatment of Fragile X Syndrome

Financial news for ADHD dated on 2014-04-10: Alcobra Issues Protocol to FDA for Phase IIb Study of Metadoxine ER for Treatment of Fragile X Syndrome

Financial news for ADHD dated on 2014-02-19: Alcobra Appoints J.P. Morgan Banker Dr. Tomer Berkovitz as Chief Financial Officer

Financial news for ADHD dated on 2014-02-19: Alcobra Announces Udi Bilboa to Step Down as Acting CFO

Financial news for ADHD dated on 2014-02-13: Alcobra Pharma Reports Q4 EPS of \$(0.45)

Financial news for ADHD dated on 2014-02-07: Alcobra Announces IND Submission to FDA for Extended Release Metadoxine to Treat Adults With ADHD

Financial news for ADHD dated on 2014-01-02: Aegis Capital Rates Alcobra as a Top Pick in 2014

Financial news for ADHD dated on 2014-01-02: Aegis Capital Calls Alcobra 'A Top Pick in 2014,' Maintains Buy Rating, \$40 Target

Financial news for ADHD dated on 2013-12-18: UPDATE: FDA Grants Orphan Drug Status to Metadoxine in Fragile X Syndrome

Financial news for ADHD dated on 2013-12-18: FDA Confirms Alcobra Granted Orphan Drug Designation for Metadoxine in Fragile X Syndrome

Financial news for ADHD dated on 2013-12-17: Alcobra Receives FDA Orphan Designation for Metadoxine for Fragile X Syndrome

Financial news for ADHD dated on 2013-12-04: UPDATE: Stifel Initiates Coverage on Alcobra as Company Regains Focus in Market

Financial news for ADHD dated on 2013-12-04: Stifel Nicolaus Initiates Coverage on Alcobra Pharma at Buy, Announces \$27.00 PT

Financial news for ADHD dated on 2013-11-22: Alcobra Says Data Show Metadoxine Could Lack Human Abuse Potential

Financial news for ADHD dated on 2013-11-05: Alcobra Reports Successful Completion of Enrollment in Comparative Phase II Study in PI-ADHD

Financial news for ADHD dated on 2013-10-30: Alcobra Closes Offering of 2.3M Shares at \$16.50/Share for Gross Proceeds \$38M

Financial news for ADHD dated on 2013-10-28: Investing In Future IPOs: With SEC Changes, Investors Get Ready To Invest In Startups

Financial news for ADHD dated on 2013-10-25: Alcobra Prices 2 Share Offering at \$16.50/Share

Financial news for ADHD dated on 2013-10-15: F-1 Filing from Alcobra Shows Prospectus for Ordinary Shares

Financial news for ADHD dated on 2013-10-14: Alcobra Says MG01CI No Effect on Dopamine/Noradrenaline Targets

Financial news for ADHD dated on 2013-10-04: Stocks Hitting 52-Week Highs

Financial news for ADHD dated on 2013-09-10: Alcobra's Pre-Clinical Study for MG01CI Shows Significant Positive Results

Financial news for ADHD dated on 2013-08-26: US Stock Futures Down; Durable-Goods Data In Focus

Financial news for ADHD dated on 2013-08-26: Alcobra Enrolls First Patient in MG01CI Study for Patients With PI-ADHD

Financial news for ADHD dated on 2013-07-30: Alcobra Ltd. Appoints Dr. Jonathan Rubin as Chief Medical Officer

Financial news for ADHD dated on 2013-07-10: Shares of Alcobra Up 30+% This Week Even as Article from Monday 'ADHD Drugs Don't Boost Kids' Grades' Now a Top Story on WSJ.com

Financial news for ADHD dated on 2013-07-08: Aegis Capital Initiates Coverage on Alcobra Pharma at Buy, Announces \$30.00 PT

Financial news for ADHD dated on 2013-06-24: Alcobra Announces Patent Issuance for #8,476,304

Financial news for ADHD dated on 2013-05-29: Knoll Capital Mgmt Files 13G on Alcobra Ltd. Showing 5.3% Stake

Financial news for ADHD dated on 2013-05-22: Alcobra Shares Open ~\$8.25

Financial news for ADHD dated on 2013-05-22: Alcobra Priced IPO of 3.125M Shares at \$8/Share, Initial Range Was for 1.365M Shares at \$10-12/Share; Issue Now Open for Quote, Expected to Open for Trade at 10:20AM EDT

Financial news for ADHD dated on 2013-01-14: Alcobra Pharma Filed \$18.75M IPO

Financial news for ADHD dated on 2013-01-14: Alcobra Pharma Filed \$18.75M IPO